Loading cancer entity…
Loading cancer entity…
Variants & evidence
6 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Dabrafenib + Trametinib + VemurafenibCombination | Digestive System Neuroendocrine TumorALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1430BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited dura… (full text at CIViC) PMID 27048246 · Klempner et al., 2016 · Open in CIViC | civic |
| KDR Overexpression1 | ||||||||
| Pazopanib | Neuroendocrine Tumor | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7854Phase 2 study of pazopanib in pretreated advanced neuroendocrine tumors. Study found that patients with immunoexpression of VEGFR2 (KDR) above the median had longer PFS (12.6 months vs 9.1 months, P=… (full text at CIViC) PMID 26063633 · Grande et al., 2015 · Open in CIViC | civic |
| MEN1 Loss-of-function1 | ||||||||
| JQ1 | Neuroendocrine Tumor | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID9249Neuroendocrine tumors (NETs) of the pancreas (PNETs) and bronchus (BNETs) have mutations of the multiple endocrine neoplasia type 1 (MEN1) gene, which encodes menin that modifies histones by interacti… (full text at CIViC) PMID 28504695 · Lines et al., 2017 · Open in CIViC | civic |
| MGMT Underexpression1 | ||||||||
| Temozolomide | Neuroendocrine Tumor | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2904Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19… (full text at CIViC) PMID 19118063 · Kulke et al., 2009 · Open in CIViC | civic |
| SSTR5 Overexpression1 | ||||||||
| Pasireotide | Neuroendocrine Tumor | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID10193Phase II study of pasireotide in metastatic neuroendocrine tumours enrolled 29 patients. Overall median PFS was 11 months (95% CI, 7.6–16 months). High SSTR5 expression (seen in 17/22 samples measured… (full text at CIViC) PMID 25376618 · Cives et al., 2015 · Open in CIViC | civic |
| High1 | ||||||||
| Temozolomide | Pancreatic Neuroendocrine Tumor | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13033Temozolomide (TMZ), the principal alkylating agent used in PanNET, drives acquisition of a hypermutator phenotype through direct mutagenesis. In a paired pre/post-TMZ cohort (23 patients), a hypermuta… (full text at CIViC) PMID 41244370 · Taboada et al., 2025 · Open in CIViC | civic |
Data updated 15 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.